Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Hepatobiliary Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Hepatobiliary Neoplasm

Cancer Family

Hepatobiliary Neoplasm

CI-CAN-00000198Explore in graph →

Non-malignant1,187 active trials17 approved drugs42 evidence items

NCIt: C8614

Overview
Statistics
Survival
Genomics32
Variants & evidence42
Drugs25
Trials5262
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (128)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 76–100 of 128 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
· Lancet Gastroenterol Hepatol · 2021 · PMID 34358484 · validated civic_curation pubmed
DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
· Mod Pathol · 2015 · PMID 25698061 · validated civic_curation pubmed
Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.
· Science · 2014 · PMID 24578576 · validated civic_curation pubmed
Unique genomic profile of fibrolamellar hepatocellular carcinoma.
· Gastroenterology · 2015 · PMID 25557953 · validated civic_curation pubmed
Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
· Hepatology · 2014 · PMID 24122810 · validated civic_curation pubmed
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Retracted
· N Engl J Med · 2015 · PMID 26287849 · validated civic_curation pubmed
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
· J Clin Oncol · 2018 · PMID 29182496 · validated civic_curation

Showing 76–100 of 128 publications

← Previous
1
2
3
4
5
6
Next →

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

· J Clin Oncol · 2018 · PMID 29320312 · validated civic_curation pubmed

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

· Cancer Discov · 2019 · PMID 31575541 · validated civic_curation pubmed

Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

· JCO Precis Oncol · 2025 · PMID 41100773 · validated civic_curation pubmed

High expression of HEF1 predicts a poorer prognosis of hepatocellular carcinoma: A retrospective study.

· Mol Clin Oncol · 2016 · PMID 26893853 · validated civic_curation pubmed

Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma.

· BMC Cancer · 2015 · PMID 26674738 · validated civic_curation pubmed

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

· J Clin Oncol · 2017 · PMID 27870574 · validated civic_curation pubmed

GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma.

· Neoplasia · 2007 · PMID 17356712 · validated civic_curation pubmed

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

· Br J Cancer · 2019 · PMID 30420614 · validated civic_curation pubmed

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

· Lancet Gastroenterol Hepatol · 2019 · PMID 31300360 · validated civic_curation pubmed

Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

· JCO Precis Oncol · 2019 · PMID 35100714 · validated civic_curation pubmed

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.

· Br J Cancer · 2012 · PMID 22596232 · validated civic_curation pubmed

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

· Clin Cancer Res · 2014 · PMID 25294897 · validated civic_curation pubmed

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.

· PLoS Genet · 2014 · PMID 24550739 · validated civic_curation pubmed

Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.

· Ann Oncol · 2017 · PMID 28950338 · validated civic_curation pubmed

Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion.

· J Gastrointest Oncol · 2017 · PMID 28480077 · validated civic_curation pubmed

Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review.

· J Gastrointest Oncol · 2016 · PMID 28078132 · validated civic_curation pubmed

Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.

· Ecancermedicalscience · 2014 · PMID 25435907 · validated civic_curation pubmed

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.

· J Gastrointest Cancer · 2016 · PMID 26687137 · validated civic_curation pubmed